Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by garygpon Jul 02, 2021 4:57pm
176 Views
Post# 33488337

Disappointment for PMN AGM.

Disappointment for PMN AGM.The vote for the current BOD is a real disappointment.  The ball  is now in the hands of the FSG to see how they handle this dilema.  Goldstein and Williams have pounded PMN into the stoneage under the guidance of the previous Board, unfortunately now the new Board.  Our only hope now  is for Cashman and the SAB to unleash groundbreaking scientific data and deals that can be taken to the bank or we will continue to languish at these ridiculous share prices all summer.  It's very difficult to watch the struggle taking place here as there is no real reason for it other than an inept BOD.

Goldstein is gone and that's start, but the journey to progress is going to be a mighty task.  And those 18.2 million shares withheld for Williams, was from two investors.

I think its time for significant shareholders to mount a campaign and have a serious chat with the FSG and see what their plans are to advance the company.  If acton isn't taken soon to identify a revenue stream, rest assured more financings will be a given and the inevitable share consolidation to follow.

This crapp has to cease.  Who knows, may be are headed into private hands, and why not?
<< Previous
Bullboard Posts
Next >>